PIB is a non-specific imaging marker of amyloid-beta (A ) peptide-related cerebral amyloidosis
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(4'-methylaminophenyl-6-hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer's disease (AD) and to date has been assumed to bind with high affinity and specificity to the amyloid structures associated with classical plaques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investigated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during in vivo imaging scans. Using a combination of autoradiography and histochemical techniques, we demonstrate that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy (CAA). The interaction of PIB with CAA was not fully displaceable and this may be linked to the apolipoprotein E-epsilon4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was markedly lower than that associated with the amyloid-beta (Abeta) pathology. The data provide a molecular explanation for PIB's limited specificity in diagnosing and monitoring disease progression in AD and instead indicate that the ligand is primarily a non-specific marker of Abeta-peptide related cerebral amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Images of adjacent MFG sections from two Category A pathology cases (A1in A^C ; A2 in D^G ), showing correspondence of [3H]-PIB binding ( A and D ) with 6E10-immunoreactive A b deposits ( C and F ). NDB is demonstrated in sections treated with the non-radioactive competitive ligand BTA-1 ( B and E ). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining artefacts on 6E10 sections. Higher power representative images of boxed area from case A2 arranged in consecutive cryostat order ( G ). Selected corresponding pathological features are highlighted in pink (DPs), orange (CPs) and blue (CAA). Scale bar 1mm.](https://figures.cochat.ai/paper-figures/53cf42bb40d34aaf9b53cf4f09ffbcbc/pib-is-a-non-specific-imaging-marker-of-amyloid-beta-a-peptide-related-cerebral-figure-1.png)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pittsburgh Compound B retention is not specific for CAA as opposed to Alzheimer disease, because the compound binds to both vascular and parenchymal amyloid158; however, the 2 pathologies may be distinguishable in part by the relative occipital predominance of labeling in CAA.156,157”
From Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association (2011) · cites this paper as [158]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 5×
“…vivo observations with data from both the large number of antecedent postmortem studies detailing the regional, microscopic spread of AD pathology (Braak and Braak, 1991a; Berg et al., 1998; Price and Morris, 1999) and the relatively sparse literature characterizing the interaction of imaging…”
BackgroundMethodInfluentialMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 5×
“Additionally, an inverse correlation of PIB retention with the pattern of decreased regional cerebral glucose metabolism rate (rCMRglc) has been observed (Klunk et al., 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).”
BackgroundResultInfluentialConsortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 3×
“…retention of [11C]-PIB in brain regions not normally associated with a high CP load such as the striatum and frontal cortex (Klunk et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007) cannot readily be explained by the reported specificity of PIB for CPs.”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979 · cited 1×
“…protocols used in this study differ significantly from the previous studies investigating the interaction of PIB with human brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004; Bacskai et al., 2007) and that these may explain the novel findings associated with the current study.”
Alzheimer’s amyloid fibrils: structure and assembly
Serpell, L. C. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00029-6 · Cited by 959 · cited 1×
“Both Ab, which forms the fibrils variably associated with SPs (and cerebrovascular amyloid), and tau, which forms the paired helical and straight filaments associated with NFTs, are types of amyloid (Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).”
Background
Research works printed but not linked: 3
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothia- zoles as amyloid imaging agents. J Med Chem 2003; 46: 2740-54.
- Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67: 446-52.
- Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007; 68: 1205-12.
Cited by
Items 101–200 of 311
Amyloid PET imaging: applications beyond Alzheimer’s disease
Catafau, A. M., & Bullich, S. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0098-3 · Cited by 71
“Amyloid PET tracer binding to fibrillar amyloid in perivascular beta-amyloid depositions (hallmark of CAA) in addition to beta-amyloid plaques in the cerebral parenchyma (hallmark of AD), has been reported using C-PIB [32, 33] which hass been the most extensively used tracer to investigate the potential clinical utili…”
BackgroundNeuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
“Since Aβ imaging tracers are not specific to DPs or NPs [23], it is possible that the in vivo associations between Aβ deposition and cognition are confounded by the presence of DPs.”
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Wang, J., Jin, C., Zhou, J., Zhou, R., Tian, M., Lee, H. J., & Zhang, H. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05999-z · Cited by 76
Kantarci, K., Lowe, V., Przybelski, S. A., Senjem, M. L., Weigand, S. D., Ivnik, R. J., Roberts, R., Geda, Y. E., Boeve, B. F., Knopman, D. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822dc7e1 · Cited by 71
Buckley, C. J., Sherwin, P. F., Smith, A. P. L., Wolber, J., Weick, S. M., & Brooks, D. J. (2017) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000633 · Cited by 69
Formaglio, M., Costes, N., Seguin, J., Tholance, Y., Bars, D. L., Roullet‐Solignac, I., Mercier, B., Krolak‐Salmon, P., & Vighetto, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6030-0 · Cited by 74
“Human PET studies have shown significantly higher neocortical retention of [C]PIB in AD than controls [14, 15], reflecting the presence of Ab plaques and amyloid angiopathy [16–18].”
BackgroundPreclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 76
Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 78
“PET using tracers for Aβ is employed to detect accumulation of the amyloid plaques as a hallmark of Alzheimer’s disease (Lockhart et al 2007).”
MethodCerebral white matter lesions – associations with Aβ isoforms and amyloid PET
van Westen, D., Lindqvist, D., Blennow, K., Minthon, L., Nägga, K., Stomrud, E., Zetterberg, H., & Hansson, O. (2016) · Scientific Reports · doi:10.1038/srep20709 · Cited by 66
Vandenberghe, R. R., Nelissen, N., Salmon, É., Ivanoiu, A., Hasselbalch, S. G., Andersen, A., Kørner, A., Minthon, L., Brooks, D. J., Laere, K. V., et al. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.09.015 · Cited by 74
“…analogue (Koole et al., 2009; Nelissen et al., 2009; Vandenberghe et al., 2010) of 11 C-Pittsburgh Compound B (PIB) (Klunk et al., 2003, 2004; Lockhart et al., 2007; Ikonomovic et al., 2008), 27 patients with clinically probable AD, 25 healthy controls and 20 patients with amnestic mild…”
Diagnostic imaging of Alzheimer's disease with copper and technetium complexes
Hickey, J. L., & Donnelly, P. S. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.035 · Cited by 73
Amyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 61
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
“However, Aβ-PET ligands such as carbon-11 labelled Pittsburgh Compound-B ([11C] PiB) have been shown to also bind in vitro to diffuse plaques (DPs) and cerebral amyloid angiopathy (CAA) (Lockhart et al., 2007).”
A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis
Daniela, P., Orazio, S., Alessandro, P., Mariano, N. F., Leonardo, I., Pasquale Anthony, D. R., Giovanni, F., & Carlo, C. (2014) · BioMed Research International · doi:10.1155/2014/785039 · Cited by 58
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 67
Early Detection of Alzheimer’s Disease with PET Imaging
Berti, V., Osorio, R. S., Mosconi, L., Li, Y., Santi, S. D., & de Leon, M. J. (2010) · Neurodegenerative Diseases · doi:10.1159/000289222 · Cited by 62
“These findings, when considered together with pathology reports that PIB may not be specific for dense classical Aβ plaques [”
BackgroundAβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
Villemagne, V. L., Klunk, W. E., Mathis, C. A., Rowe, C. C., Brooks, D. J., Hyman, B. T., Ikonomović, M. D., Ishii, K., Jack, C. R., Jagust, W. J., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2045-0 · Cited by 59
Cortical phase changes in Alzheimer's disease at 7T MRI: A novel imaging marker
van Rooden, S., Versluis, M. J., Liem, M. K., Milles, J., Maier, A. B., Oleksik, A. M., Webb, A. G., van Buchem, M. A., & van der Grond, J. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.002 · Cited by 55
“2014 The Alzheimer’s Association.”
Imaging Alzheimer's disease pathophysiology with PET
Schilling, L. P., Zimmer, E. R., Shin, M., Leuzy, A., Pascoal, T. A., Benedet, A. L., Borelli, W. V., Palmini, A., Gauthier, S., & Rosa-Neto, P. (2016) · Dementia & Neuropsychologia · doi:10.1590/s1980-5764-2016dn1002003 · Cited by 52
Esiri, M., Chance, S., Joachim, C., Warden, D., Smallwood, A., Sloan, C., Christie, S., Wilcock, G., & Smith, A. D. (2015) · Brain Pathology · doi:10.1111/bpa.12221 · Cited by 55
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?
Mosconi, L., & McHugh, P. F. (2011) · PubMed · Cited by 72
Huang, K., Lin, K., Hsiao, I., Kuo, H., Hsu, W., Chuang, W., Kung, M., Wey, S., Hsieh, C., Wai, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058974 · Cited by 61
“On the other hand, PET radiotracers may fail to bind amyloid plaques because different fibrillary amyloid aggregate forms may have different affinities for amyloid radiotracers [36,37].”
BackgroundLowe, V. J., Lundt, E. S., Senjem, M. L., Schwarz, C. G., Min, H.-K., Przybelski, S. A., Kantarci, K., Knopman, D., Petersen, R. C., & Jack, C. R. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.204271 · Cited by 55
“Previously, 11C-PiB was also shown to bind a wide range of fibrillar Ab pathology, including diffuse plaques and cerebrovascular amyloid angiopathy, which affects both GM and WM (39).”
BackgroundAyubcha, C., Revheim, M.-E. R., Newberg, A. B., Moghbel, M. C., Rojulpote, C., Werner, T. J., & Alavi, A. A. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04926-4 · Cited by 58
Molecular polymorphism of Aβ in Alzheimer's disease
LeVine, H., & Walker, L. C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.026 · Cited by 52
“When 3H-PIB is applied to AD histological sections, dense-core plaques, CAA and some diffuse Aβ deposits bind the agent, but NFTs do not [14,31].”
Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech
Utianski, R. L., Whitwell, J. L., Schwarz, C. G., Senjem, M. L., Tosakulwong, N., Duffy, J. R., Clark, H. M., Machulda, M. M., Petersen, R. C., Jack, C. R., et al. (2018) · Cortex · doi:10.1016/j.cortex.2017.12.021 · Cited by 51
Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis
Almeida, Z. L., Vaz, D. C., & Brito, R. M. M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04543-4 · Cited by 52
Imaging Frontotemporal Lobar Degeneration
Diehl‐Schmid, J., Onur, O. A., Kuhn, J., GRUPPE, T. L., & Drzezga, A. E. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0489-x · Cited by 52
Cerebral Amyloidosis: Postmortem Detection with Human 7.0-T MR Imaging System
van Rooden, S., Maat-Schieman, M. L. C., Nabuurs, R. J. A., van der Weerd, L., van Duijn, S., van Duinen, S. G., Natté, R., van Buchem, M. A., & van der Grond, J. (2009) · Radiology · doi:10.1148/radiol.2533090490 · Cited by 49
Tsai, H.-H. C., Tsai, L., Chen, Y., Tang, S., Lee, B., Yen, R., & Jeng, J. (2017) · Scientific Reports · doi:10.1038/srep44715 · Cited by 49
Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., Rowe, C. C., Leyton, C. E., Kwok, J. B. J., Ittner, L. M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.05.005 · Cited by 48
Imaging the Role of Amyloid in PD Dementia and Dementia with Lewy Bodies
Gomperts, S. N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0472-6 · Cited by 47
Evaluation of a visual interpretation method for tau‐PET with 18 F‐flortaucipir
Sonni, I., Lesman‐Segev, O. H., Baker, S. L., Iaccarino, L., Korman, D., Rabinovici, G. D., Jagust, W. J., Landau, S. M., Joie, R. L., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12133 · Cited by 53
Neuropathological correlates of amyloid PET imaging in Down syndrome
Abrahamson, E. E., Head, E., Lott, I. T., Handen, B. L., Mufson, E. J., Christian, B. T., Klunk, W. E., & Ikonomovic, M. D. (2019) · Developmental Neurobiology · doi:10.1002/dneu.22713 · Cited by 45
“As in amyloid plaques, Aβ in CAA also contributes to amyloid PET ligand retention in vivo (Bacskai et al., 2007; Lockhart et al., 2007).”
BackgroundMatsumura, K., Ono, M., Hayashi, S., Kimura, H., Okamoto, Y., Ihara, M., Takahashi, R., Mori, H., & Saji, H. (2011) · MedChemComm · doi:10.1039/c1md00034a · Cited by 45
A Strategy for Designing a Peptide Probe for Detection of β‐Amyloid Oligomers
Hu, Y., Su, B., Kim, C., Hernandez, M. X., Rostagno, A. A., Ghiso, J. A., & Kim, J. R. (2010) · ChemBioChem · doi:10.1002/cbic.201000435 · Cited by 47
Mi, Z., Halfter, W. M., Abrahamson, E. E., Klunk, W. E., Mathis, C. A., Mufson, E. J., & Ikonomović, M. D. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw062 · Cited by 43
Dugger, B. N., Serrano, G. E., Sue, L. I., Walker, D. G., Adler, C. H., Shill, H. A., Sabbagh, M. N., Caviness, J. N., Hidalgo, J., Saxon-LaBelle, M., et al. (2012) · Journal of Parkinson’s Disease · doi:10.3233/jpd-2012-11073 · Cited by 41
“It also appears likely, based on postmortem autoradiography studies with antemortem amyloid imaging, that all types of A amyloid, including diffuse, cored and neuritic plaques as well as amyloid angiopathy, will elicit strong amyloid imaging signals [61, 63, 64].”
Self-citationJensen, J. R., Cisek, K. K., Funk, K. E., Naphade, S. B., Schafer, K. N., & Kuret, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-0003 · Cited by 46
“PIB binds both plaques and tangles [47], which may limit the sensitivity of the multitracer approach.”
Holm, P. C., Ettrup, A., Klein, A. B., Santini, M. A., Hervig, M. E.-S., Elvang, A. B., Stensbøl, T. B., Mikkelsen, J. D., Knudsen, G. M., & Aznar, S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100117 · Cited by 42
“The in vivo imaging probe [C]-PIB is a recently developed positron emission tomography (PET) radioligand that binds with high affinity and specificity to the amyloid structures associated with classical plaques [37–39].”
Du, D., Murray, A. N., Cohen, E., Kim, H.-E., Simkovsky, R., Dillin, A. G., & Kelly, J. W. (2011) · Biochemistry · doi:10.1021/bi1013744 · Cited by 42
Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?
Edison, P., Hinz, R., Ramlackhansingh, A., Thomas, J., Gelosa, G., Archer, H. A., Turkheimer, F. E., & Brooks, D. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.099 · Cited by 39
“of PIB binding has been disputed in another study (Lockhart et al., 2007).”
Grand'Maison, M., Zehntner, S. P., Ho, M.-K., Hébert, F., Wood, A., Carbonell, F., Zijdenbos, A. P., Hamel, E., & Bedell, B. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.02.005 · Cited by 38
“PiB PET, however, is not sensitive to soluble, prefibrillar, or polymorphic forms of β-amyloid (Leinonen et al., 2008; Lockhart et al., 2007; Rosen et al., 2010).”
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Biological basis for amyloidogenesis in Alzheimer’S disease
Andreeva, T. V., Lukiw, W. J., & Rogaev, E. I. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917020043 · Cited by 36
18F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
Moscoso, A., Silva‐Rodríguez, J., Aldrey, J. M., Cortés, J., Peleteiro, J. M. P., Ruibal, Á., Aguiar, P., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05493-y · Cited by 40
Henderson, T. A. (2012) · CNS Spectrums · doi:10.1017/s1092852912000636 · Cited by 41
Dugger, B. N., Clark, C. M., Serrano, G., Mariner, M., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Lu, M., Fleisher, A. S., Reiman, E. M., et al. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000028 · Cited by 38
“These sub-groups consisted of those with LBs, white matter rarefaction (WMR), severe cerebral amyloid angiopathy (CAA), Args, and phosphorylated TDP-43 inclusions.”
BackgroundInfluentialSelf-citationA History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 41
Self-citationAmyloid-plaque imaging in early and differential diagnosis of dementia
Drzezga, A. E. (2010) · Annals of Nuclear Medicine · doi:10.1007/s12149-009-0330-9 · Cited by 40
“It is known that there is a broad overlap regarding the protein deposition pathologies of neurodegenerative diseases [ 53 , 57].”
BackgroundSojkova, J., & M. Resnick, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745375 · Cited by 36
“Since 2004, the PET radioligand 11C-Pittsburgh Compound-B (PiB) has allowed in vivo quantification of fibrillar β-amyloid (Aβ) [6–9].”
BackgroundNoble, J. M., & Scarmeas, N. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)00407-3 · Cited by 38
The prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 36
“It is a neutral derivative of the histological dye thioflavin-T and in AD brain slices it shows a nanomolar affinity for the extracellular and intravascular fibrillar deposits of Aβ and low affinity toward the amorphous amyloid deposits, soluble Aβ and intracellular NFTs [24, 25].”
BackgroundZha, Z., Jin, S., Choi, S., Wu, Z., Plöessl, K., Smith, M., & Kung, H. F. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00127 · Cited by 37
Preclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease
Svedberg, M. M., Rahman, O., & Hall, H. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.10.007 · Cited by 35
Amyloid Imaging in Alzheimer’s Disease and Other Dementias
Fodero‐Tavoletti, M. T., Cappai, R., McLean, C., Pike, K. E., Adlard, P. A., Cowie, T., Connor, A. R., Masters, C. L., Rowe, C. C., & Villemagne, V. L. (2009) · Brain Imaging and Behavior · doi:10.1007/s11682-009-9067-2 · Cited by 34
“(Klunk et al. 2003b; Fodero-Tavoletti et al. 2007; Lockhart et al. 2007; Ikonomovic et al. 2008)”
BackgroundMethodInfluentialβ-Amyloid PET and 123 I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia
Chen, Q., Lowe, V. J., Boeve, B. F., Przybelski, S. A., Miyagawa, T., Senjem, M. L., Jack, C. R., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011454 · Cited by 33
Optimizing phase II of drug development for disease‐modifying compounds
Cummings, J. L. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.10.002 · Cited by 31
Tuzzi, E., Balla, D. Z., Loureiro, J. R., Neumann, M., Laske, C., Pohmann, R., Preische, O., Scheffler, K., & Hagberg, G. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190424 · Cited by 35
Li, Y., Zhou, K., Zhang, X., Zhao, H., Wang, X., Dong, R., Wang, Y., Chen, B., Yan, X., Dai, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01503 · Cited by 34
Teipel, S. J., Buchert, R., Thome, J., Hampel, H. J., & Pahnke, J. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.004 · Cited by 36
“, 2000) or the neurochemical validity of a marker to specifically bind to Abcontaining amyloid plaques in the brain (Lockhart et al., 2007).”
Arbizu, J., García‐Ribas, G., Carrió, I., Garrastachu, P., Martínez‐Lage, P., & Molinuevo, J. L. (2015) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2015.03.002 · Cited by 36
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease
Shirvan, J. C., Clement, N. F., Ye, R., Katz, S. R., Schultz, A. P., Johnson, K. A., Gómez‐Isla, T., Frosch, M. P., Growdon, J. H., & Gomperts, S. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007855 · Cited by 33
Amyloid PET Ligands for Dementia
Villemagne, V. L., & Rowe, C. C. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.008 · Cited by 32
Regional analysis of striatal and cortical amyloid deposition in patients with A lzheimer's disease
Ishibashi, K., Ishiwata, K., Toyohara, J., Murayama, S., & Ishii, K. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12633 · Cited by 32
“However, a PET amyloid tracer, 11C-PiB, can detect both diffuse and dense plaques, although its affinity for dense plaques is much higher than that for diffuse plaques (Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundYotter, R. A., Doshi, J. J., Clark, V., Sojkova, J., Zhou, Y., Wong, D. F., Ferrucci, L., Resnick, S. M., & Davatzikos, C. A. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.030 · Cited by 31
“Spatial heterogeneity of patterns of amyloid deposition have also been found using recentlydeveloped in vivo amyloid tracers (Lockhart et al., 2007).”
BackgroundAmyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease
Ni, R., Gillberg, P., Bogdanović, N., Viitanen, M. H., Myllykangas, L., Nennesmo, I., Långström, B., & Nordberg, A. K. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.08.006 · Cited by 30
Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue
Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Simic, G., Doran, E., Lott, I., Carroll, S., Bharani, K., Thomas, S., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00414-3 · Cited by 26
Design of a Coumarin-Based Fluorescent Probe for Efficient In Vivo Imaging of Amyloid-β Plaques
Cao, Y., Liu, X., Zhang, J., Liu, Z., Fu, Y., Zhang, D., Zheng, M., Zhang, H., & Xu, M. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00468 · Cited by 29
Alzheimer's Disease and the “Valley of Death”: Not Enough Guidance from Human Brain Tissue?
Beach, T. G. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129020 · Cited by 28
Self-citationPiB Fails to Map Amyloid Deposits in Cerebral Cortex of Aged Dogs with Canine Cognitive Dysfunction
Fast, R., Rodell, A. B., GJEDDE, A. H., Mouridsen, K., Alstrup, A. K. O., Bjarkam, C. R., West, M. J., Berendt, M., & Møller, A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00099 · Cited by 28
“…of Aβ in human studies with PET (Klunk et al., 2004; Price et al., 2005; Mintun Frontiers in Aging Neuroscience www.frontiersin.org December 2013 | Volume 5 | Article 99 | 1 et al., 2006; Lockhart et al., 2007; Ikonomovic et al., 2008; Gulyas et al., 2012; Gjedde et al., 2013; Rodell et al., 2013).”
BackgroundResultAutomated 11C-PiB Standardized Uptake Value Ratio
Raniga, P., Bourgeat, P., Fripp, J., Acosta, O., Villemagne, V. L., Rowe, C. C., Masters, C. L., Jones, G. R., O'Keefe, G. J., Salvado, O., et al. (2008) · Academic Radiology · doi:10.1016/j.acra.2008.07.006 · Cited by 28
Recent advances in ophthalmic molecular imaging
de Carvalho, E. R., Verbraak, F. D., Aalders, M. C. G., Noorden, C. J. F. V., & Schlingemann, R. O. (2013) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.09.005 · Cited by 28
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 28
Jia, J., Cui, M., Dai, J., & Liu, B. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00209 · Cited by 26
Molecular Imaging of Alzheimer Disease Pathology
Kantarci, K. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3847 · Cited by 23
“One of the key applications of A PET imaging in clinical practice is in the differential diagnosis of AD.”
BackgroundInfluentialBlood-brain transfer of Pittsburgh compound B in humans
GJEDDE, A. H., Aanerud, J., Brændgaard, H., & Rodell, A. B. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00070 · Cited by 25
“Although other tracers currently are under evaluation (Wong et al., 2013), [11C]PiB is the most extensively examined marker of Aβ in human studies with PET (Klunk et al., 2004; Price et al., 2005; Mintun et al., 2006; Lockhart et al., 2007; Ikonomovic et al., 2008).”
BackgroundInfluentialApplications of nanotechnology in molecular imaging of the brain
McAteer, M. A., & Choudhury, R. P. (2009) · Progress in brain research · doi:10.1016/s0079-6123(08)80004-0 · Cited by 26
High throughput object-based image analysis of β-amyloid plaques in human and transgenic mouse brain
Samaroo, H., Opsahl, A., Schreiber, J., O'Neill, S., Marconi, M., Qian, J., Carvajal‐Gonzalez, S., Tate, B. A., Milici, A. J., Bales, K. R., et al. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.10.003 · Cited by 25
Jagust, W. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832d93c7 · Cited by 24
Schafer, K. N., Kim, S., Matzavinos, A., & Kuret, J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.066 · Cited by 24
“As a result, the uptake of even nonselective radiotracers such as PIB and FDDNP (Lockhart et al., 2007; Thompson et al., 2009) correlates primarily with Aβ pathology (Shin et al.”
Tanaka, T., Stephenson, M. C., Nai, Y., Khor, D., Saridin, F. N., Hilal, S., Villaraza, S. G., Gyanwali, B., Ihara, M., Vrooman, H. A., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04642-8 · Cited by 22
Diner, I., Dooyema, J. M., Gearing, M., Walker, L. C., & Seyfried, N. T. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00500 · Cited by 23
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Cerebral amyloid angiopathy distribution in older people: A cautionary note
Alakbarzade, V., French, J. M. R., Howlett, D. R., Attems, J., Francis, P. T., Stratton, S., Clark, C. N., Pereira, A. C., & Hainsworth, A. H. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12145 · Cited by 22
Nabuurs, R. J. A., Natté, R., de Ronde, F. M., Hegeman-Kleinn, I. M., Dijkstra, J., van Duinen, S. G., WEBB, A. G., Rozemüller, A. J. M., van Buchem, M. A., & van der Weerd, L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122215 · Cited by 21
“However, its ability to delineate diffuse plaques and even NFTs has also been reported in a postmortem study [33].”
Jorge, L., Martins, R., Canário, N., Xavier, A. C., Abrunhosa, A., Santana, I. J., & Castelo-Branco, M. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200840 · Cited by 22
Seven-Tesla MRI and neuroimaging biomarkers for Alzheimer’s disease
Ali, R., Goubran, M., Choudhri, O., & Zeineh, M. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.9.focus15326 · Cited by 21
Kalheim, L. F., Fladby, T., Coello, C. S., Bjørnerud, A., & Selnes, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170582 · Cited by 20
“11C-PiB is also shown to label vascular amyloid depositions [28, 29] as well as cortical deposits, a feature that may also be attributable to 18F-Flut given their structural similarities.”
BackgroundJakubovic, R. Y., & Aviv, R. I. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00086 · Cited by 20
“These observations, together with that of others confirm that both vascular CAA and AD plaque uptake may coexist in the same patient (Bacskai et al., 2003; Silva et al., 2005; Johnson et al., 2007; Klunk et al., 2007; Lockhart et al., 2007; Remes et al., 2008; Ly et al., 2010).”
BackgroundResultForsberg, A., Juréus, A., Cselényi, Z., Eriksdotter, M., Freund‐Levi, Y., Jeppsson, F., Swahn, B., Sandell, J., Julin, P., Schou, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2322-6 · Cited by 23
“[(3)H]AZD2995 selectively labelled both diffuse plaques and dense core plaques in a similar manner to [(3)H]PIB [36], [(3)H] AZD2184 [13] and [(3)H]AZD4694 [15], while only core plaques were labelled in transgenic mice (Fig.”
ResultAdvances in molecular imaging for the diagnosis of dementia
Okamura, N., Fodero‐Tavoletti, M. T., Kudo, Y., Rowe, C. C., Furumoto, S., Arai, H., Masters, C. L., Yanai, K., & Villemagne, V. L. (2009) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050903133790 · Cited by 19
Delatour, B., Epelbaum, S., Petiet, A., & Dhénain, M. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/604853 · Cited by 20
“Despite its advantages, PiB presents several limitations: it can display high retention in the brain of aged nondemented subjects [17]; it does not readily detect soluble oligomeric Aβ conformations considered to be highly pathogenic [18]; it shows high affinity for vascular amyloid deposits that may vary from one pat…”
BackgroundWillroider, M., Roeber, S., Horn, A. K. E., Arzberger, T., Scheifele, M., Respondek, G., Sabri, O., Barthel, H., Patt, M., Mishchenko, O., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.684523 · Cited by 18
Fang, Y., Wang, Q., Xiang, C., Liu, G., & Li, J. (2023) · Biosensors · doi:10.3390/bios13060610 · Cited by 18
“These methods are cumbersome, of low specificity, have a short half-life, are expensive, and have unavoidable limitations due to radiation risks to humans [9].”
BackgroundJi, B., Chen, C.-J., Bando, K., Ashino, H., Shiraishi, H., Sano, H., Kasahara, H., Minamizawa, T., YAMADA, K., Ono, M., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13293 · Cited by 17
Drzezga, A. E. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0697-6 · Cited by 20
“The binding of the tracer [11C]PIB to NFTs has been previously evaluated and is currently regarded to be negligible [42, 43].”
BackgroundMouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Sundaram, G. S. M., Garai, K., Rath, N. P., Yan, P., Cirrito, J. R., Cairns, N. J., Lee, J., & Sharma, V. (2014) · Organic Letters · doi:10.1021/ol501264q · Cited by 16
Metadata
- Authors
- Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., Libri, V., Leppert, D., & Beach, T. G.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- University Hospital of Basel (CH)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-01
- Volume
- 130
- Issue
- 10
- Pages
- 2607-2615
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2031309116
- Cited by
- 302
- References
- 55
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 2 · 2023: 3 · 2022: 8 · 2021: 15 · 2020: 11 · 2019: 9 · 2018: 9 · 2017: 13 · 2016: 15 · 2015: 18 · 2014: 17 · 2013: 25 · 2012: 35
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research (211002, P30 AG19610)
- GlaxoSmithKline
- Arizona Department of Health Services (P30 AG19610, 211002, Contract 211002)
- Arizona Biomedical Research Commission (P30 AG19610, contract 0011, 211002)
- National Institute on Aging (211002, P30-AG-19610, AG-19610, P30AG019610)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- Pittsburgh compound B, [11C]PIB, amyloid-beta, cerebral amyloidosis, Alzheimer's disease, diffuse plaques, neurofibrillary tangles, APOE ε4, autoradiography, amyloid imaging
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Brain, Carbon Radioisotopes, Humans, Thiazoles, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.